Rentschler Biopharma appoints Mark Caswell as Vice President, Site Head for US facility

CDMO Rentschler Biopharma has appointed Mark Caswell as Vice President, Site Head at the company’s US operations.

Caswell joined the company July 2022 and is managing all operations at the company’s US facilities in Milford, MA, including the completion of the new state-of-the-art Rentschler Biopharma Manufacturing Center (RBMC) adjacent to the existing site.

Caswell has more than 25 years of experience in the biopharmaceutical industry. Prior to joining Rentschler Biopharma, he worked for over six years at Lonza Biologicals, most recently as Head of Operations at the Portsmouth, NH site. At Lonza, he supported the design, construction, start up and transition to operations of a facility based on single-use technology, including responsibility for the entire site operations of nearly 1,400 people as the interim Site Head.

Before that, he worked for many years at Sanofi Genzyme (previously Genzyme) in positions of increasing responsibility, most recently as Director, Global Engineering and Technology. While there, he led the transformation of a local engineering organization into a global center of excellence for operational, technical and reliability engineering and maintenance.

At Rentschler, part of Caswell’s new role will be overseeing the completion of the state-of-the-art RBMC facility: the largest expansion in Rentschler Biopharma’s 150-year history.

Laupheim, Germany headquartered Rentschler Biopharma has had a US footprint since 2019, acquiring a manufacturing facility in Milford, MA. Since then, the company has expanded capacity and gained certification as a multi-product site, and, in the summer of 2021, broke ground for the RBMC that will double the company’s commercial manufacturing capacity.

The RBMC is adjacent to the current site and will add 22,000 square feet of manufacturing cleanroom space and house four new 2,000 L single-use bioreactors, in addition to being highly automated and leveraging industry 4.0 solutions.

Part of Caswell’s new role will be to oversee the completion of this facility: the largest expansion in the company’s 150-year history.

With the appointment of Mark Caswell and Rentschler Biopharma’s growth in the US, the company has implemented changes to its governance structure. The responsibilities of Dr. Martin Kessler in his role as CEO of Rentschler Biopharma Inc. have been transferred to Mark Caswell.